Guidelines for the indications to test for and to treat Helicobacter pylori infection: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 24: Line 24:
However, for those who are tested and found to be infected, treatment should be offered, acknowledging that effects on GERD symptoms are unpredictable
However, for those who are tested and found to be infected, treatment should be offered, acknowledging that effects on GERD symptoms are unpredictable
|-
|-
 
|5.Patients initiating chronic treatment with a non-steroidal anti-inflammatory drug (NSAID) should be tested for H. pylori infection. Those who test positive
should be offered eradication therapy
|-


|}
|}
{|class="wikitable"  
{| class="wikitable"  
|-
| colspan="1" style="text-align:center; background:LemonChiffon" |Conditional recommendation
|-
| bgcolor="LemonChiffon" |'''1.'''In patients with uninvestigated dyspepsia who are under the age of 60 years and without alarm features, non-endoscopic testing for H. pylori infection is a
consideration. Those who test positive should be offered eradication therapy.
|-
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| bgcolor="LemonChiffon" |2.In patients taking long-term, low-dose aspirin, testing for H. pylori infection could be considered to reduce the risk of ulcer bleeding. Those who test positive
should be offered eradication therapy to reduce the risk of ulcer bleeding.
|-
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''In patients with [[Peripheral arterial disease|PAD]] and an abnormal resting ABI (≤0.90), exercise treadmill ABI testing can be useful to objectively assess functional status. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])''<nowiki>"</nowiki>
| bgcolor="LemonChiffon" |3. The benefit of testing and treating H. pylori in a patient already taking an NSAID remains unclear.
|-
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' In patients with normal (1.00–1.40) or borderline (0.91–0.99) ABI in the setting of nonhealing wounds or gangrene, it is reasonable to diagnose CLI by using TBI with waveforms, transcutaneous oxygen pressure (TcPO2), or skin perfusion pressure (SPP). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' In patients with [[Peripheral arterial disease|PAD]] with an abnormal ABI (≤0.90) or with noncompressible arteries (ABI >1.40 and TBI ≤0.70) in the setting of nonhealing wounds or gangrene, TBI with waveforms, TcPO2, or SPP can be useful to evaluate local perfusion. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])''<nowiki>"</nowiki>
|4.Patients with unexplained iron deficiency anemia despite an appropriate evaluation should be tested for H. pylori infection. Those who test positive should
be offered eradication therapy.
|-
|-
|Adults with idiopathic thrombocytopenic purpura (ITP) should be tested for H. pylori infection. Those who test positive should be offered eradication
therapy.
|}
|}

Revision as of 01:07, 1 December 2017


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2], Sargun Singh Walia M.B.B.S.[3]


2017 ACG guidelines for the indications to test for and to treat Helicobacter pylori infection

Strong recommendation
1.Since all patients with a positive test of active infection with H. pylori should be offered treatment, the critical issue is which patients should be tested for the

infection .

2.All patients with active peptic ulcer disease (PUD), a past history of PUD (unless previous cure of H. pylori infection has been documented), low-grade

gastric mucosa-associated lymphoid tissue (MALT) lymphoma or a history of endoscopic resection of early gastric cancer (EGC) should be tested for H.

pylori infection. Those who test positive should be offered treatment for the infection.

3. When upper endoscopy is undertaken in patients with dyspepsia, gastric biopsies should be taken to evaluate for H. pylori infection. Infected patients

should be offered eradication therapy.

4.Patients with typical symptoms of gastroesophageal reflux disease (GERD) who do not have a history of PUD need not be tested for H. pylori infection.

However, for those who are tested and found to be infected, treatment should be offered, acknowledging that effects on GERD symptoms are unpredictable

5.Patients initiating chronic treatment with a non-steroidal anti-inflammatory drug (NSAID) should be tested for H. pylori infection. Those who test positive

should be offered eradication therapy

Conditional recommendation
1.In patients with uninvestigated dyspepsia who are under the age of 60 years and without alarm features, non-endoscopic testing for H. pylori infection is a

consideration. Those who test positive should be offered eradication therapy.

2.In patients taking long-term, low-dose aspirin, testing for H. pylori infection could be considered to reduce the risk of ulcer bleeding. Those who test positive

should be offered eradication therapy to reduce the risk of ulcer bleeding.

3. The benefit of testing and treating H. pylori in a patient already taking an NSAID remains unclear.
4.Patients with unexplained iron deficiency anemia despite an appropriate evaluation should be tested for H. pylori infection. Those who test positive should

be offered eradication therapy.

Adults with idiopathic thrombocytopenic purpura (ITP) should be tested for H. pylori infection. Those who test positive should be offered eradication

therapy.

Retrieved from "https://www.wikidoc.org/index.php?title=Guidelines_for_the_indications_to_test_for_and_to_treat_Helicobacter_pylori_infection&oldid=1399808"